| scholarly article | Q13442814 |
| P356 | DOI | 10.7326/0003-4819-156-8-201204170-00001 |
| P8608 | Fatcat ID | release_spsnjjr44rhhrelqx3gacjrsai |
| P932 | PMC publication ID | 3690921 |
| P698 | PubMed publication ID | 22508731 |
| P50 | author | Douglas K Owens | Q98149051 |
| Margaret Brandeau | Q59750489 | ||
| Jessie L Juusola | Q59768210 | ||
| P2093 | author name string | Eran Bendavid | |
| P2860 | cites work | Cost-effectiveness of HIV screening in acute care settings | Q71016446 |
| Clinical and epidemiologic features of primary HIV infection | Q71182378 | ||
| Natural history of HIV-1 infection | Q73362895 | ||
| The NIMH Multisite HIV Prevention Trial: reducing HIV sexual risk behavior. The National Institute of Mental Health (NIMH) Multisite HIV Prevention Trial Group | Q74668138 | ||
| Costs of HIV medical care in the era of highly active antiretroviral therapy | Q77889196 | ||
| Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisexual men | Q95824189 | ||
| Estimated HIV incidence in the United States, 2006-2009 | Q21135528 | ||
| The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States | Q22242768 | ||
| Quality-of-life weights for the US population: self-reported health status and priority health conditions, by demographic characteristics | Q23915053 | ||
| Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies | Q24597052 | ||
| Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men | Q24612082 | ||
| Prevention of HIV-1 infection with early antiretroviral therapy | Q24634688 | ||
| HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness | Q28474086 | ||
| Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine | Q28477312 | ||
| Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group | Q29614934 | ||
| Brief but efficient: acute HIV infection and the sexual transmission of HIV. | Q30341429 | ||
| Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009. | Q30383449 | ||
| A rapid review of rapid HIV antibody tests | Q33235819 | ||
| Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network | Q33933954 | ||
| Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men | Q34012348 | ||
| Laboratory testing for infection with the human immunodeficiency virus: established and novel approaches. | Q34076859 | ||
| Pre-exposure prophylaxis state of the science: empirical analogies for research and implementation | Q34123592 | ||
| High-value, cost-conscious health care: concepts for clinicians to evaluate the benefits, harms, and costs of medical interventions | Q34161821 | ||
| Trends in medical spending by age, 1963-2000. | Q34342102 | ||
| The contribution of steady and casual partnerships to the incidence of HIV infection among homosexual men in Amsterdam | Q34532967 | ||
| Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings | Q34567572 | ||
| Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection | Q34740804 | ||
| The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States | Q35214966 | ||
| Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies | Q36285986 | ||
| Estimation of HIV prevalence, risk factors, and testing frequency among sexually active men who have sex with men, aged 18-64 years--New York City, 2002. | Q36440666 | ||
| Preference-Based EQ-5D index scores for chronic conditions in the United States | Q36541277 | ||
| The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men | Q36627938 | ||
| How many sexually-acquired HIV infections in the USA are due to acute-phase HIV transmission? | Q36649584 | ||
| Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. | Q36793483 | ||
| The cost-effectiveness of symptom-based testing and routine screening for acute HIV infection in men who have sex with men in the USA. | Q36854378 | ||
| Comparing the costs of HIV screening strategies and technologies in health-care settings | Q36935852 | ||
| Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education | Q37137347 | ||
| Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel | Q37234205 | ||
| Potential population health outcomes and expenditures of HIV vaccination strategies in the United States | Q37376820 | ||
| Behavior change following diagnosis with acute/early HIV infection-a move to serosorting with other HIV-infected individuals. The NIMH Multisite Acute HIV Infection Study: III. | Q37449021 | ||
| Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings | Q37834013 | ||
| Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. Project RESPECT Study Group | Q37880029 | ||
| Potential impact of antiretroviral therapy on HIV-1 transmission and AIDS mortality in resource-limited settings | Q38852564 | ||
| HIV-1 transmission, by stage of infection | Q38875941 | ||
| Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda | Q38881073 | ||
| Associations of race/ethnicity with HIV prevalence and HIV-related behaviors among young men who have sex with men in 7 urban centers in the United States | Q39678805 | ||
| Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness | Q40054244 | ||
| Human immunodeficiency virus (HIV) risk, prevention, and testing behaviors--United States, National HIV Behavioral Surveillance System: men who have sex with men, November 2003-April 2005. | Q40309186 | ||
| Diagnosis and management of adults with pharyngitis. A cost-effectiveness analysis | Q40554916 | ||
| Risk factors and clinical presentation of acute primary HIV infection in India | Q40644160 | ||
| Men who have sex with men in the United States: demographic and behavioral characteristics and prevalence of HIV and HSV-2 infection: results from National Health and Nutrition Examination Survey 2001-2006. | Q43062162 | ||
| Determinants of the cost of health services used by veterans with HIV. | Q43428451 | ||
| Oseltamivir for treatment of influenza in healthy adults: pooled trial evidence and cost-effectiveness model for Canada | Q44365190 | ||
| Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy | Q44404808 | ||
| The effect of diagnosis with HIV infection on health-related quality of Life | Q45107449 | ||
| HIV intervention for providers study: a randomized controlled trial of a clinician-delivered HIV risk-reduction intervention for HIV-positive people. | Q46029835 | ||
| A meta-analysis of utility estimates for HIV/AIDS. | Q46061609 | ||
| Sex hustling, injection drug use, and non-gay identification by men who have sex with men. Associations with high-risk sexual behaviors and condom use. | Q46418265 | ||
| Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy | Q46624490 | ||
| HIV prevalence estimates--United States, 2006. | Q46880600 | ||
| HIV transmission under highly active antiretroviral therapy | Q47220771 | ||
| Awareness and Use of HIV Pre-Exposure Prophylaxis Among Attendees of a Seattle Gay Pride Event and Sexually Transmitted Disease Clinic | Q48785809 | ||
| The cost-effectiveness of influenza vaccination of healthy adults 50-64 years of age. | Q50124678 | ||
| The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors | Q50126848 | ||
| Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs | Q50176584 | ||
| The economic burden of HIV in the United States in the era of highly active antiretroviral therapy: evidence of continuing racial and ethnic differences. | Q50660038 | ||
| Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. | Q50712911 | ||
| Expanded screening for HIV in the United States--an analysis of cost-effectiveness. | Q50756519 | ||
| Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia. | Q51108701 | ||
| Discordance between sexual behavior and self-reported sexual identity: a population-based survey of New York City men. | Q51131517 | ||
| Unintentional HIV exposures from young men who have sex with men who disclose being HIV-negative. | Q51155801 | ||
| Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. | Q51157878 | ||
| Relation between HIV viral load and infectiousness: a model-based analysis. | Q51691573 | ||
| Primary HIV infection as source of HIV transmission within steady and casual partnerships among homosexual men. | Q51989833 | ||
| Sexual risk behaviors and implications for secondary HIV transmission during and after HIV seroconversion. | Q52036335 | ||
| High-risk behaviors among men who have sex with men in 6 US cities: baseline data from the EXPLORE Study | Q56897894 | ||
| Current CD4 Cell Count and the Short‐Term Risk of AIDS and Death before the Availability of Effective Antiretroviral Therapy in HIV‐Infected Children and Adults | Q59119626 | ||
| Economic analysis of needle exchange | Q59558608 | ||
| United States life tables, 2004 | Q64127169 | ||
| Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs | Q64132033 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | United States of America | Q30 |
| men who have sex with men | Q853451 | ||
| prevention of HIV/AIDS | Q7242372 | ||
| P304 | page(s) | 541-550 | |
| P577 | publication date | 2012-04-01 | |
| P1433 | published in | Annals of Internal Medicine | Q564416 |
| P1476 | title | The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men | |
| P478 | volume | 156 |
| Q38760898 | 2020, sexually transmissible infections and HIV in gay, bisexual and other men who have sex with men. |
| Q59803716 | A mathematical model of biomedical interventions for HIV prevention among men who have sex with men in China |
| Q37034865 | A practical online tool to estimate antiretroviral coverage for HIV infected and susceptible populations needed to reduce local HIV epidemics. |
| Q34697242 | Acceptability and willingness among men who have sex with men (MSM) to use a tablet-based HIV risk assessment in a clinical setting. |
| Q91744994 | Acceptability of electronic healthcare predictive analytics for HIV prevention: a qualitative study with men who have sex with men in New York City |
| Q35102317 | Accuracy of highly sexually active gay and bisexual men's predictions of their daily likelihood of anal sex and its relevance for intermittent event-driven HIV pre-exposure prophylaxis |
| Q38660885 | An Evaluation of a Clinical Pre-Exposure Prophylaxis Education Intervention among Men Who Have Sex with Men. |
| Q31063168 | An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis |
| Q34077715 | Antiretroviral chemoprophylaxis: state of evidence and the research agenda |
| Q28085433 | Antiretrovirals for primary HIV prevention: the current status of pre- and post-exposure prophylaxis |
| Q39145460 | Are Centers for Disease Control and Prevention Guidelines for Preexposure Prophylaxis Specific Enough? Formulation of a Personalized HIV Risk Score for Pre-Exposure Prophylaxis Initiation |
| Q38165803 | Assessing the cost effectiveness of pre-exposure prophylaxis for HIV prevention in the US. |
| Q42650176 | Awareness and willingness towards pre-exposure prophylaxis against HIV infection among individuals seeking voluntary counselling and testing for HIV in Taiwan: a cross-sectional questionnaire survey |
| Q34968312 | Challenges and opportunities for oral pre-exposure prophylaxis in the prevention of HIV infection: where are we in Europe? |
| Q38657576 | Challenges in Translating PrEP Interest into Uptake in an Observational Study of Young Black MSM. |
| Q34294277 | Clinical effectiveness and cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men: risk calculators for real-world decision-making |
| Q36480354 | Community member perspectives from transgender women and men who have sex with men on pre-exposure prophylaxis as an HIV prevention strategy: implications for implementation |
| Q92554496 | Competing biomedical HIV prevention strategies: potential cost-effectiveness of HIV vaccines and PrEP in Seattle, WA |
| Q47644938 | Considerable interest in pre-exposure prophylaxis uptake among men who have sex with men recruited from a popular geosocial-networking smartphone application in London. |
| Q38105957 | Controlling the HIV epidemic with antiretrovirals: IAPAC consensus statement on treatment as prevention and preexposure prophylaxis |
| Q35158119 | Cost effectiveness of 'on demand' HIV pre-exposure prophylaxis for non-injection drug-using men who have sex with men in Canada |
| Q89905960 | Cost utility analysis of HIV pre exposure prophylaxis among men who have sex with men in Israel |
| Q39825094 | Cost-Effectiveness of HIV Preexposure Prophylaxis for People Who Inject Drugs in the United States |
| Q37298218 | Cost-Effectiveness of Pre-exposure HIV Prophylaxis During Pregnancy and Breastfeeding in Sub-Saharan Africa |
| Q40528328 | Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study |
| Q98945089 | Cost-effectiveness analysis of pre-exposure prophylaxis for the prevention of HIV in men who have sex with men in South Korea: a mathematical modelling study |
| Q48537541 | Cost-effectiveness of alternative strategies for provision of HIV pre-exposure prophylaxis for people who inject drugs |
| Q47237872 | Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation |
| Q91574011 | Cost-effectiveness of preexposure prophylaxis for HIV prevention for conception in the United States |
| Q40055245 | Developing a Web-Based Geolocated Directory of HIV Pre-Exposure Prophylaxis-Providing Clinics: The PrEP Locator Protocol and Operating Procedures. |
| Q92181796 | Development and Calibration of a Dynamic HIV Transmission Model for 6 US Cities |
| Q28658226 | Early experiences implementing pre-exposure prophylaxis (PrEP) for HIV prevention in San Francisco |
| Q92831029 | Effect of 'lifestyle stigma' on public support for NHS-provisioned pre-exposure prophylaxis (PrEP) and preventative interventions for HPV and type 2 diabetes: a nationwide UK survey |
| Q28539234 | Effectiveness and cost effectiveness of oral pre-exposure prophylaxis in a portfolio of prevention programs for injection drug users in mixed HIV epidemics |
| Q92180090 | Efficacy and cost-effectiveness of early antiretroviral therapy and partners' pre-exposure prophylaxis among men who have sex with men in Shenyang, China: a prospective cohort and costing study |
| Q58076931 | Elimination prospects of the Dutch HIV epidemic among men who have sex with men in the era of preexposure prophylaxis |
| Q38084940 | Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis |
| Q37161853 | Engaging healthcare providers to implement HIV pre-exposure prophylaxis |
| Q64982916 | Estimated Impact of Targeted Pre-Exposure Prophylaxis: Strategies for Men Who Have Sex with Men in the United States. |
| Q33724701 | Estimation of the cost-effectiveness of HIV prevention portfolios for people who inject drugs in the United States: A model-based analysis |
| Q36016811 | Evaluating the impact of prioritization of antiretroviral pre-exposure prophylaxis in New York |
| Q50224009 | Evolving Models and Ongoing Challenges for HIV Preexposure Prophylaxis Implementation in the United States |
| Q36276035 | Explaining the Efficacy of Pre-exposure Prophylaxis (PrEP) for HIV Prevention: A Qualitative Study of Message Framing and Messaging Preferences Among US Men Who have Sex with Men. |
| Q64103435 | Factors Associated With Sex-Related Pre-exposure Prophylaxis Adherence Among Men Who Have Sex With Men in New York City in HPTN 067 |
| Q47549573 | Functional Knowledge of Pre-Exposure Prophylaxis for HIV Prevention Among Participants in a Web-Based Survey of Sexually Active Gay, Bisexual, and Other Men Who Have Sex With Men: Cross-Sectional Study. |
| Q92918284 | Global implementation of PrEP for HIV prevention: setting expectations for impact |
| Q64066784 | Gonorrhoea and chlamydia diagnosis as an entry point for HIV pre-exposure prophylaxis: a modelling study |
| Q36682112 | HIV Incidence Among Men Who Have Sex With Men After Diagnosis With Sexually Transmitted Infections |
| Q28552357 | HIV Incidence and Predictors of Incident HIV among Men Who Have Sex with Men Attending a Sexual Health Clinic in Melbourne, Australia |
| Q36642710 | HIV Treatment and Prevention: A Simple Model to Determine Optimal Investment |
| Q34046430 | HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial |
| Q28244216 | HIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society-USA Panel |
| Q47162251 | HIV transmission and pre-exposure prophylaxis in a high risk MSM population: A simulation study of location-based selection of sexual partners |
| Q36866833 | HIV-Negative Partnered Men's Willingness to Use Pre-Exposure Prophylaxis and Associated Factors Among an Internet Sample of U.S. HIV-Negative and HIV-Discordant Male Couples |
| Q30877918 | High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project |
| Q37525283 | High risk for HIV following syphilis diagnosis among men in Florida, 2000-2011. |
| Q28552455 | How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health Impact |
| Q39110309 | I Am Men's Health: Generating Adherence to HIV Pre-Exposure Prophylaxis (PrEP) in Young Men of Color Who Have Sex with Men. |
| Q39321915 | Impact of Population Recruitment on the HIV Epidemics and the Effectiveness of HIV Prevention Interventions |
| Q50051642 | In what circumstances could nondaily preexposure prophylaxis for HIV substantially reduce program costs? |
| Q35139980 | Indices to measure risk of HIV acquisition in Rakai, Uganda |
| Q36654828 | Modeling and Cost-Effectiveness in HIV Prevention |
| Q89415225 | Modelling the Epidemiological Impact and Cost-Effectiveness of PrEP for HIV Transmission in MSM in China |
| Q37605831 | Motives of Dutch men who have sex with men for daily and intermittent HIV pre-exposure prophylaxis usage and preferences for implementation: A qualitative study |
| Q33751621 | Optimal costs of HIV pre-exposure prophylaxis for men who have sex with men |
| Q37281199 | Optimizing HIV pre-exposure prophylaxis implementation among men who have sex with men in a large urban centre: a dynamic modelling study |
| Q51064420 | Optimizing Pre-Exposure Antiretroviral Prophylaxis Adherence in Men Who Have Sex with Men: Results of a Pilot Randomized Controlled Trial of "Life-Steps for PrEP". |
| Q90565401 | Optimizing access to PrEP based on MSM preferences: results of a discrete choice experiment |
| Q47111394 | Options for affordable pre-exposure prophylaxis (PrEP) in national HIV prevention programmes in Europe |
| Q36409225 | Oral antiretroviral chemoprophylaxis: current status |
| Q27023352 | Oral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: opportunities and challenges |
| Q35904606 | Perceptions of and intentions to adopt HIV pre-exposure prophylaxis among black men who have sex with men in Los Angeles |
| Q40049420 | Plasma Tenofovir-levels to Support Adherence to TDF/FTC Pre-exposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California |
| Q90714592 | Potential Impact of Targeted HIV Pre-Exposure Prophylaxis Uptake Among Male Sex Workers |
| Q43241737 | PrEP Implementation Science: State-of-the-Art and Research Agenda |
| Q28080301 | Pre-exposure Prophylaxis for HIV Prevention: Why, What, Who and How |
| Q40723562 | Pre-exposure Prophylaxis in Primary Care--A New Era in HIV Prevention |
| Q37296618 | Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services |
| Q36853885 | Preexposure prophylaxis for adolescents and young adults at risk for HIV infection: is an ounce of prevention worth a pound of cure? |
| Q40073013 | Preexposure prophylaxis for men who have sex with men and transgender persons in early adopting countries: a narrative review |
| Q38944859 | Psychosocial Functioning and Decisional Balance to Use Condoms in a Racially/Ethnically Diverse Sample of Young Gay/Bisexual Men Who Have Sex with Men. |
| Q36905593 | Racial differences and correlates of potential adoption of preexposure prophylaxis: results of a national survey |
| Q49921922 | Recent advances in pre-exposure prophylaxis for HIV. |
| Q91994872 | Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States |
| Q36399819 | Risk stratification in compartmental epidemic models: Where to draw the line? |
| Q38256787 | Role of oral pre-exposure prophylaxis (PrEP) in current and future HIV prevention strategies |
| Q58601530 | Sensitivity of joint contagiousness and susceptibility-based dynamic optimal control strategies for HIV prevention |
| Q90295319 | Social network intervention to increase pre-exposure prophylaxis (PrEP) awareness, interest, and use among African American men who have sex with men |
| Q37061624 | Systemic and topical drugs for the prevention of HIV infection: antiretroviral pre-exposure prophylaxis |
| Q35575958 | Targeting pre-exposure prophylaxis among men who have sex with men in the United States and Peru: partnership types, contact rates, and sexual role |
| Q33855920 | The Potential Cost-Effectiveness of Pre-Exposure Prophylaxis Combined with HIV Vaccines in the United States |
| Q93270300 | The Relative Impact of Community and Hospital Antibiotic Use on the Selection of Extended-spectrum Beta-lactamase-producing Escherichia coli |
| Q28487926 | The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies |
| Q47810963 | The cost of science : knowledge and ethics in the HIV pre-exposure prophylaxis trials |
| Q51731801 | The cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil. |
| Q52567034 | The cost-effectiveness of oral HIV pre-exposure prophylaxis and early antiretroviral therapy in the presence of drug resistance among men who have sex with men in San Francisco. |
| Q39404544 | The importance of extended high viremics in models of HIV spread in South Africa |
| Q28484308 | The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling study |
| Q42271267 | Top Questions in ID: Pre-exposure Prophylaxis for HIV. |
| Q57185057 | Trajectories and Predictors of Longitudinal Preexposure Prophylaxis Adherence Among Men Who Have Sex With Men |
| Q35875746 | Translating PrEP effectiveness into public health impact: key considerations for decision-makers on cost-effectiveness, price, regulatory issues, distributive justice and advocacy for access |
| Q36816377 | Use of antiretrovirals for HIV prevention: what do we know and what don't we know? |
| Q104738144 | Utilizing emergency departments for pre-exposure prophylaxis (PrEP) |
| Q37626053 | Vulnerable infected populations and street markets for ARVs: Potential implications for PrEP rollout in the USA. |
| Q37215398 | What primary care providers need to know about preexposure prophylaxis for HIV prevention: a narrative review |
| Q37229172 | Willingness to Take, Use of, and Indications for Pre-exposure Prophylaxis Among Men Who Have Sex With Men-20 US Cities, 2014. |
| Q38717420 | Willingness to use pre-exposure prophylaxis among Black and White men who have sex with men in Atlanta, Georgia |
Search more.